Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In vivo Model

Elif Beyzanur Polat; Hümeysa Kiyak-Kırmacı; Büşra Ertaş; Kübra Elçioğlu

doi:10.12991/jrespharm.1804622

Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In vivo Model

Abstract

Neuroinflammation, which results from alterations in the immune system, plays a central role in the pathophysiology of major depressive disorder by inducing neurotoxic effects in brain regions involved in emotion regulation. Agomelatine (AGO), a novel antidepressant, may influence emotional regulation by modulating the critical mechanisms of the interaction between autophagy and neuroinflammation. Lipopolysaccharide (LPS) is an endotoxin that causes depression-like behavior by increasing microglial activation and inflammatory response in the brain. To evaluate the anxiolytic and anti-inflammatory effects of agomelatine, a rat model of depression was induced with LPS. A total of 24 male rats were used in this study, divided into three experimental groups (n=8): control, LPS, and LPS+AGO. Rats in the LPS and LPS+AGO groups received AGO (40 mg/kg, intragastrically) and LPS (0.5 mg/kg, i.p.) for the first 10 days, respectively. AGO was administered daily to the LPS+AGO group for of the 21-day study period. Behavioral assessments were conducted using the open field test. At the conclusion of the experiment, IL-1β and IL-10 levels were measured in the hippocampus, prefrontal cortex, and serum samples using ELISA. According to these results, AGO was found to significantly increase IL-10 levels, particularly in the prefrontal cortex, while decreasing IL-1β levels in the hippocampus. These results confirmed that agomelatine has anxiolytic and anti-inflammatory effects.

Keywords

References

[1] Colonna M and Butovsky O. Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annu Rev Immunol. 2017; 35: 441-468. https://doi.org/10.1146/annurev-immunol-051116-052358
[2] Glass CK, Saijo K, Winner B, Marchetto MC, and Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140(6): 918-34. https://doi.org/10.1016/j.cell.2010.02.016
[3] Guo B, Zhang M, Hao W, Wang Y, Zhang T, and Liu C. Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. Translational Psychiatry. 2023; 13(1): 5. https://doi.org/10.1038/s41398-022-02297-y
[4] Dantzer R, O'Connor JC, Freund GG, Johnson RW, and Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008; 9(1): 46-56. https://doi.org/10.1038/nrn2297
[5] Barbosa-Méndez S, Perez-Sánchez G, and Salazar-Juárez A. Agomelatine decreases cocaine-induced locomotor sensitisation and dopamine release in rats. World J Biol Psychiatry. 2023; 24(5): 400-413. https://doi.org/10.1080/15622975.2022.2123954
[6] Conboy L, Tanrikut C, Zoladz PR, Campbell AM, Park CR, Gabriel C, Mocaer E, Sandi C, and Diamond DM. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol. 2009; 12(3): 329-41. https://doi.org/10.1017/S1461145708009255
[7] Savran M, Aslankoc R, Ozmen O, Erzurumlu Y, Savas HB, Temel EN, Kosar PA, and Boztepe S. Agomelatine could prevent brain and cerebellum injury against LPS-induced neuroinflammation in rats. Cytokine. 2020; 127: 154957. https://doi.org/10.1016/j.cyto.2019.154957
[8] Chumboatong W, Khamchai S, Tocharus C, Govitrapong P, and Tocharus J. Agomelatine Exerts an Anti-inflammatory Effect by Inhibiting Microglial Activation Through TLR4/NLRP3 Pathway in pMCAO Rats. Neurotox Res. 2022; 40(1): 259-266. https://doi.org/10.1007/s12640-021-00447-6

[9] Lu Y, Ho CS, McIntyre RS, Wang W, and Ho RC. Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sci. 2018; 210: 177-184. https://doi.org/10.1016/j.lfs.2018.09.003
[10] Mendonça IP, Paiva IHR, Duarte-Silva EP, Melo MG, Silva RSD, Oliveira WH, Costa B, and Peixoto CA. Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity. Int Immunopharmacol. 2022; 102: 108415. https://doi.org/10.1016/j.intimp.2021.108415
[11] Zhang J, Zhang N, Lei J, Jing B, Li M, Tian H, Xue B, and Li X. Fluoxetine shows neuroprotective effects against LPS-induced neuroinflammation via the Notch signaling pathway. Int Immunopharmacol. 2022; 113(Pt A): 109417. https://doi.org/10.1016/j.intimp.2022.109417
[12] Wang YL, Han QQ, Gong WQ, Pan DH, Wang LZ, Hu W, Yang M, Li B, Yu J, and Liu Q. Microglial activation mediates chronic mild stress-induced depressive- and anxiety-like behavior in adult rats. J Neuroinflammation. 2018; 15(1): 21. https://doi.org/10.1186/s12974-018-1054-3
[13] Aranđelović J, Ivanović J, Batinić B, Mirković K, Matović BD, and Savić MM. Sucrose binge-eating and increased anxiety-like behavior in Sprague-Dawley rats exposed to repeated LPS administration followed by chronic mild unpredictable stress. Sci Rep. 2024; 14(1): 22569. https://doi.org/10.1038/s41598-024-72450-8
[14] Zhang N, Gao X, Li D, Xu L, Zhou G, Xu M, Peng L, Sun G, Pan F, Li Y, Ren R, Huang R, Yang Y, and Wang Z. Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites. Microbiol Spectr. 2024; 12(4): e0143723. https://doi.org/10.1128/spectrum.01437-23
[15] Cai L, Gong Q, Qi L, Xu T, Suo Q, Li X, Wang W, Jing Y, Yang D, Xu Z, Yuan F, Tang Y, Yang G, Ding J, Chen H, and Tian H. ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway. Cell Commun Signal. 2022; 20(1): 56. https://doi.org/10.1186/s12964-022-00862-y
[16] Goulart da Silva M, Daros GC, Santos FP, Yonamine M, and de Bitencourt RM. Antidepressant and anxiolytic-like effects of ayahuasca in rats subjected to LPS-induced neuroinflammation. Behav Brain Res. 2022; 434: 114007. https://doi.org/10.1016/j.bbr.2022.114007
[17] Lan T, Wu Y, Zhang Y, Li S, Zhu Z, Wang L, Mao X, Li Y, Fan C, Wang W, and Yu SY. Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Gαi-2-PKA-ASK1 signaling pathway. J Neuroinflammation. 2022; 19(1): 117. https://doi.org/10.1186/s12974-022-02479-x
[18] Kakhki FSH, Asghari A, Bardaghi Z, Anaeigoudari A, Beheshti F, Salmani H, and Hosseini M. The Antidiabetic Drug Metformin Attenuated Depressive and Anxiety-like Behaviors and Oxidative Stress in the Brain in a Rodent Model of Inflammation Induced by Lipopolysaccharide in Male Rats. Endocr Metab Immune Disord Drug Targets. 2024; 24(13): 1525-1537. https://doi.org/10.2174/0118715303275039231228065050
[19] Algaidi SA. Chronic stress-induced neuroplasticity in the prefrontal cortex: Structural, functional, and molecular mechanisms from development to aging. Brain Research. 2025; 1841: 149461. https://doi.org/10.1016/j.brainres.2025.149461

Details

Primary Language

English

Subjects

Basic Pharmacology

Journal Section

Research Article

Authors

Elif Beyzanur Polat
0000-0002-3093-3595
Türkiye

Hümeysa Kiyak-Kırmacı
0000-0003-2574-4762
Türkiye

Büşra Ertaş
0000-0001-8374-1098
Türkiye

Kübra Elçioğlu ^*
0000-0001-6386-1711
Türkiye

Publication Date

May 11, 2026

Submission Date

October 15, 2025

Acceptance Date

December 2, 2025

Published in Issue

Year 2026 Volume: 30 Number: 3

DOI

https://doi.org/10.12991/jrespharm.1804622

IZ

https://izlik.org/JA69FY64EH

Cite

RIS / Bibtex

APA

Polat, E. B., Kiyak-Kırmacı, H., Ertaş, B., & Elçioğlu, K. (2026). Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In vivo Model. Journal of Research in Pharmacy, 30(3), 756-761. https://doi.org/10.12991/jrespharm.1804622

AMA

1.Polat EB, Kiyak-Kırmacı H, Ertaş B, Elçioğlu K. Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In vivo Model. J. Res. Pharm. 2026;30(3):756-761. doi:10.12991/jrespharm.1804622

Chicago

Polat, Elif Beyzanur, Hümeysa Kiyak-Kırmacı, Büşra Ertaş, and Kübra Elçioğlu. 2026. “Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In Vivo Model”. Journal of Research in Pharmacy 30 (3): 756-61. https://doi.org/10.12991/jrespharm.1804622.

EndNote

Polat EB, Kiyak-Kırmacı H, Ertaş B, Elçioğlu K (May 1, 2026) Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In vivo Model. Journal of Research in Pharmacy 30 3 756–761.

IEEE

[1]E. B. Polat, H. Kiyak-Kırmacı, B. Ertaş, and K. Elçioğlu, “Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In vivo Model”, J. Res. Pharm., vol. 30, no. 3, pp. 756–761, May 2026, doi: 10.12991/jrespharm.1804622.

ISNAD

Polat, Elif Beyzanur - Kiyak-Kırmacı, Hümeysa - Ertaş, Büşra - Elçioğlu, Kübra. “Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In Vivo Model”. Journal of Research in Pharmacy 30/3 (May 1, 2026): 756-761. https://doi.org/10.12991/jrespharm.1804622.

JAMA

1.Polat EB, Kiyak-Kırmacı H, Ertaş B, Elçioğlu K. Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In vivo Model. J. Res. Pharm. 2026;30:756–761.

MLA

Polat, Elif Beyzanur, et al. “Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In Vivo Model”. Journal of Research in Pharmacy, vol. 30, no. 3, May 2026, pp. 756-61, doi:10.12991/jrespharm.1804622.

Vancouver

1.Elif Beyzanur Polat, Hümeysa Kiyak-Kırmacı, Büşra Ertaş, Kübra Elçioğlu. Anxiolytic and Anti-Inflammatory Effects of Agomelatine in a LPS-Induced In vivo Model. J. Res. Pharm. 2026 May 1;30(3):756-61. doi:10.12991/jrespharm.1804622